King Pharmaceuticals, Wyeth amend Altace agreement

Share this article:
King Pharmaceuticals and Wyeth have amended and restated their co-promotion agreement for King's Altace (ramipril), an angiotensin converting enzyme (ACE) inhibitor to treat high blood pressure. Effective Jan. 1, 2007, King will assume full responsibility for the selling and marketing of Altace. For the remainder of 2006, the Wyeth sales force will continue to promote the product with King, and Wyeth will receive a fee thereafter through 2010.
Share this article:
You must be a registered member of MMM to post a comment.

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.